Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1949 Views
Dr KK Aggarwal 13 September 2020
With input from Dr Monica Vasudev
[Tetraparesis resembling acute transverse myelitis in a captive chimpanzee (Pan troglodytes): long‐term care and recovery. Journal of Medical Primatology 39(5):336 – 346]
[https://casereports.bmj.com/content/13/8/e236720]
Investigators did not detect SARS-CoV-2 RNA in the CSF and postulated that this presentation was likely a result of an immune-mediated inflammatory process rather than direct invasion of SARS-CoV-2 into the CNS.
The incidence of acute myelitis associated with COVID-19 infection is not clearly understood. Three case reports of similar cases have been noted to link COVID-19 to acute myelitis as a neurological complication. The first one is in Wuhan, China by Kang Zhao et al where COVID-19 was first reported. The second is in Boston where the patient presented with symptoms of upper respiratory tract infection and then developed acute myelitis 7 days later by Sarma et al. Whether the myelitis occurs directly from the viral infection or as an autoimmune sequalae is still not known. [https://www.sciencedirect.com/science/article/pii/S1930043320302478]
Acute transverse myelitis (TM)
It is a neuro-inflammatory spinal cord disorder presenting with rapid onset of weakness, sensory alterations, and/or bowel and bladder dysfunction.
Types: Idiopathic TM occurs without a definite etiology. Secondary (disease-associated) TM is related to a systemic inflammatory autoimmune condition. Idiopathic TM is often a postinfectious complication and presumably results from an autoimmune process.
TM can be associated with infectious, systemic inflammatory, or multifocal central nervous system disease. Acquired central nervous system demyelinating disorders known to cause TM include multiple sclerosis, neuromyelitis optica, and acute disseminated encephalomyelitis.
Incidence: 1-8 new cases per million.
Onset: acute or subacute development of neurologic signs and symptoms consisting of motor, sensory, and/or autonomic dysfunction. Motor symptoms include rapidly progressing paraparesis that may involve the upper extremities; initial flaccidity followed by spasticity. In most patients, a sensory level can be identified. Sensory symptoms include pain, dysesthesia and paresthesia. Autonomic symptoms involve heightened urinary urgency, bladder and bowel incontinence, difficulty or inability to void, incomplete evacuation and bowel constipation, and sexual dysfunction.
Diagnosis: No evidence of a compressive cord lesion; exclusion of a compressive cord lesion by MRI and confirmation of inflammation by either gadolinium-enhanced MRI or lumbar puncture.
When inflammation is evident in the absence of cord compression, one must evaluate for the presence of infection, systemic inflammation, and the extent and sites central nervous system inflammation.
Acute idiopathic TM: high-dose intravenous glucocorticoid treatment.
Most patients with idiopathic TM have at least a partial recovery, which usually starts within one to three months and continues with exercise and rehabilitation therapy. Some degree of persistent disability is common, and is seen in nearly 40% of the individuals. A very rapid onset with complete paraplegia and spinal shock has been associated with poorer outcomes. Recovery can proceed over years.
Majority of patients with TM have monophasic disease. Recurrence can occur in approximately 25 to 33% of patients with idiopathic TM. With secondary TM, the recurrence rate may be nearly 70%.
Patients presenting with acute complete transverse myelitis have a risk of multiple sclerosis of only 5 to 10%. However, for patients with partial myelitis as the initial presentation and cranial MRI abnormalities showing lesions typical for multiple sclerosis, the transition rate to multiple sclerosis over three to five years is 60 to 90%. Patients with acute partial myelitis with normal brain MRI develop multiple sclerosis at a rate of only 10 to 30% over a similar time period.
Dr KK Aggarwal
President CMAAO, HCFI and Past National President IMA
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}